Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 (Fenfluramine) in Dravet Syndrome (Study 1504)
NCT02926898Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Dravet syndrome comparing ZX008 with Placebo (2 arms). Primary endpoint: Change in Convulsive Seizure Frequency From Baseline to Combined Titration + Maintenance Period at 15 weeks. Started Jan 2017; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT02926898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926898.